Evidence map›Paper›PMID 28778250›Full record

ReviewUrologic oncology2017

Current clinical trials in non-muscle invasive bladder cancer.

Mohammad Rashid Siddiqui, Campbell Grant, Thomas Sanford, Piyush K Agarwal

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Urologic oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 33 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Vaccines · 2020
    Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. New therapies in nonmuscle invasive bladder cancer treatment.Indian journal of urology : IJU : journal of the Urological Society of India
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Mohammad Rashid SiddiquiBladder Cancer Section, Urologic Oncology Branch, National Cancer Institute, NIH, Bathesda, MD.
Campbell GrantDepartment of Urology, George Washington University Medical Center, Washington, D.C.
Thomas SanfordBladder Cancer Section, Urologic Oncology Branch, National Cancer Institute, NIH, Bathesda, MD.
Piyush K AgarwalBladder Cancer Section, Urologic Oncology Branch, National Cancer Institute, NIH, Bathesda, MD. Electronic address: piyush.agarwal@nih.gov.
National Cancer Institute · US

Funding

Targeting Metabolic Pathways in Bladder CancerZIABC011741 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI AGARWAL, PIYUSH · 2016 to 2019
$796k
A Randomized, Prospective, Phase II Study to Determine the Efficacy of BacillusZIABC011528 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI AGARWAL, PIYUSH · 2013 to 2019
$667k
Intramural NIH HHS ZIA BC011528Intramural NIH HHS ZIA BC011741
6 · The paper itself

Abstract

backgroundThe treatment options for non-muscle invasive bladder cancer (NMIBC) remain limited. Bacillus Calmette-Guerin (BCG) was the last major breakthrough in bladder cancer therapy almost 4 decades ago. There have been improvements in the understanding of immune therapies and cancer biology, leading to the development of novel agents. This has led to many clinical trials that are currently underway to find the next generation of therapies for NMIBC.

methodWe reviewed clinicaltrials.org and pubmed.gov to find the recently completed and ongoing clinical trials in NIMBC. Included in this review are clinical trials that are currently active and trials that were completed in and after 2014.

resultMany trials with BCG-naive and BCG-unresponsive/recurrent/refractory/failure patients with NMIBC are either currently underway or have been recently completed. A wide variety of novel therapeutic agents are being investigated that range from cytotoxic agents to immunomodulatory agents to targeted molecular therapies. Other approaches include cancer vaccines, gene therapies, and chemoradiation potentiation agents. Novel drug-delivery methods are also being tested.

conclusionThis comprehensive update of current trials provides researchers an overview of the current clinical trial landscape for patients with NMIBC.

Indexed as

Clinical Trials as TopicCarcinoma, Transitional CellHumansUrinary Bladder NeoplasmsBCG failureBCG naiveBCG recurrentBCG refractoryBCG unresponsiveNon–muscle invasive bladder cancer

Identifiers

PMID28778250
PMCPMC5556973
OpenAlexW2741273852

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.